Top 10 Up And Coming Stocks To Watch Right Now

Top 10 Up And Coming Stocks To Watch Right Now: Arena Pharmaceuticals Inc.(ARNA)

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company?s clinical development programs include lorcaserin that has completed two pivotal Phase III clinical trials for the treatment of weight management, including weight loss and maintenance of weight loss; and APD811, which is under Phase I clinical trial for the treatment of pulmonary arterial hypertension. Its preclinical development programs include APD334, for the treatment of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis. The company also researches and develops cannabinoid, receptor agonists for the treatment of osteoarthritis and pain; and GPR119 agonists for the treatment of type 2 diabetes. Its other development programs, which had completed Phase I clinical trial include APD597 for th e treatment of type II diabetes; APD916 for the treatment of narcolepsy and cataplexy; and APD791 for the treatment of arterial thrombosis. In addition, the company provides manufacturing services. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Advisors' Opinion:

• [By James Brumley]

  Think Arena Pharmaceuticals (ARNA) and VIVUS (VVUS) used up all weight loss drug enthusiasm when the two companies won approval for Belviq and Qsymia, respectively, back in 2012?

• [By Sean Williams]

  You'll find similar impressive partnerships with Eisai. Ironically, while Takeda is licensing weight-loss drug Contrave, Eisai is licensing weight control management drug Belviq from Arena Pharmaceuticals (NASDAQ: ARNA  ) . Perhaps Eisai's most well-known strategic co-! promotion is its marketing collaboration with Pfizer for Alzheimer's disease drug Aricept.  

• [By Bryan Murphy]

  If you're curious as to why shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) are tanking following what was seemingly good news, you only have to look at the sagas of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and VIVUS, Inc. (NASDAQ:VVUS) to find your answer. Both ARNA and VVUS shares fell - precipitously - after each of those companies came up with similar (though better, technically) news. The downside for OREX shares is, not only are they apt to struggle for the same dynamic/technical reason VIVUS and Arena shares did, but the market has had a chance to see a major fundamental reason that Orexigen could be in trouble.

• [By John Udovich]

  On Tuesday, small cap EnteroMedics Inc (NASDAQ: ETRM) soared 63.5% after reporting new clinical trial data for its Maestro system that is designed to control obesity, meaning it might be time to take a closer look at the stock along with the performance of other small cap obesity drug or treatment players like Arena Pharmaceuticals, Inc (NASDAQ: ARNA), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS).

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-up-and-coming-stocks-to-watch-right-now.html